Genky DrugStores Co., Ltd. (9267) AI Stock Analysis

• Market Cap: ¥148.72B
• Dividend Yield: 0.27%
• Average Volume (3M): 65.53K
• Price to Earnings (P/E): 21.1
• Beta (1Y): 0.15
• Revenue Growth: 8.62%
• EPS Growth: 11.68%
• Country: JP
• Employees: 1,661
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 72.17
• Shares Outstanding: 30,996,967
• 10 Day Avg. Volume: 53,520
• 30 Day Avg. Volume: 65,526
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥5,046.00
• Price Target Upside: 4.15% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 70 Outperform
• Price Target: ¥5,046.00 ▲(4.15% Upside)

Genky DrugStores Co., Ltd. shows strong financial performance with consistent revenue growth and profitability, which is the most significant factor in the score. Technical analysis indicates a positive trend, but with limited momentum. Valuation is reasonable, though the low dividend yield suggests limited income potential.

Genky DrugStores Co., Ltd. Business Overview & Revenue Model

Company Description

Genky DrugStores Co., Ltd. operates a chain of drug stores. The company was founded in 1988 and is headquartered in Sakai, Japan.

How the Company Makes Money

Genky DrugStores Co., Ltd. generates revenue through the sale of a diverse array of products in its retail stores. Its primary revenue streams include the sale of pharmaceuticals, over-the-counter medicines, health and beauty products, and everyday consumer goods. The company capitalizes on its extensive store network and strategic locations to attract a steady flow of customers. Additionally, Genky DrugStores may engage in partnerships with suppliers and leverage bulk purchasing to optimize inventory costs and enhance profit margins. The company's focus on customer satisfaction and competitive pricing also plays a crucial role in maintaining its market position and driving sales.

Genky DrugStores Co., Ltd. Financial Statement Overview

Summary

Genky DrugStores Co., Ltd. demonstrates a strong financial position with consistent revenue growth and profitability. The balance sheet reflects a stable leverage position, while the income statement shows robust margins. However, the negative free cash flow highlights a need for improved cash management strategies.

Income Statement

Genky DrugStores Co., Ltd. has shown consistent revenue growth with a 4.51% increase in the latest year. The gross profit margin is healthy at approximately 20.36%, and the net profit margin has improved to 3.52%. EBIT and EBITDA margins are also stable, indicating strong operational efficiency. Overall, the income statement reflects a robust financial performance with positive growth trends.

Balance Sheet

The company's debt-to-equity ratio has improved over the years, currently at 0.64, indicating a balanced leverage position. The return on equity is strong at 13.55%, showcasing effective use of equity to generate profits. The equity ratio is stable, suggesting a solid financial structure. However, the company should continue monitoring its debt levels to maintain financial stability.

Cash Flow

Operating cash flow remains strong, but the free cash flow has turned negative, indicating potential challenges in cash generation after capital expenditures. The operating cash flow to net income ratio is healthy, but the negative free cash flow growth rate of -191.53% is a concern. The company needs to address its cash flow management to ensure long-term sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	195.66B	200.79B	184.86B	169.06B	154.64B	142.38B
Gross Profit	39.76B	40.89B	37.62B	34.55B	30.95B	30.29B
EBITDA	15.45B	16.41B	14.47B	11.73B	10.73B	10.78B
Net Income	6.74B	7.07B	6.32B	4.76B	4.42B	4.83B
Balance Sheet
Total Assets	127.25B	127.33B	113.94B	105.91B	97.12B	90.80B
Cash, Cash Equivalents and Short-Term Investments	12.03B	6.22B	5.90B	5.33B	5.44B	7.91B
Total Debt	34.54B	34.37B	30.65B	32.35B	30.96B	28.56B
Total Liabilities	76.03B	73.89B	67.26B	65.23B	60.88B	58.63B
Stockholders Equity	51.21B	53.43B	46.68B	40.68B	36.23B	32.17B
Cash Flow
Free Cash Flow	0.00	-2.50B	2.81B	-1.16B	-4.43B	3.12B
Operating Cash Flow	0.00	12.60B	13.26B	8.77B	6.08B	12.08B
Investing Cash Flow	0.00	-15.62B	-10.63B	-9.74B	-10.59B	-8.83B
Financing Cash Flow	0.00	3.35B	-2.06B	854.00M	2.04B	-1.95B

Genky DrugStores Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4845.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9267, the sentiment is Positive. The current price of 4845 is above the 20-day moving average (MA) of 4740.50, above the 50-day MA of 4521.50, and above the 200-day MA of 3531.67, indicating a bullish trend. The MACD of 101.27 indicates Negative momentum. The RSI at 60.85 is Neutral, neither overbought nor oversold. The STOCH value of 75.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:9267.

Genky DrugStores Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3391	78 Outperform	589.97B	27.47	7.73%	16.55%	4.63%	-47.30%
7649	75 Outperform	713.94B	16.93	10.25%	0.91%	20.18%	82.36%
3141	72 Outperform	574.60B	31.85	6.02%	1.28%	7.43%	-24.81%
9267	70 Outperform	¥148.72B	21.10		0.27%	8.62%	11.68%
9989	69 Neutral	530.95B	16.95	11.40%	2.86%	6.64%	6.38%
3549	64 Neutral	417.23B	22.49	12.20%	0.35%	14.79%	35.84%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Genky DrugStores Co., Ltd. Corporate Events

Genky DrugStores Reports Strong Financial Growth with Positive Outlook

Genky DrugStores Co., Ltd. reported an 8.6% increase in net sales for the fiscal year ending June 20, 2025, with net income attributable to owners rising by 11.7%. Despite a decrease in dividend payout ratio, the company’s financial position strengthened with an increase in total assets and net assets. The company forecasts continued growth in net sales and income for the fiscal year ending June 20, 2026, indicating a positive outlook for stakeholders.